Last reviewed · How we verify
PHENDIMETRAZINE TARTRATE
Phendimetrazine Tartrate is a marketed drug primarily indicated for short-term weight management. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of exclusivity post-patent expiry, which could significantly impact market share and revenue.
At a glance
| Generic name | PHENDIMETRAZINE TARTRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Short-term weight management
Common side effects
- Overstimulation
- Restlessness
- Insomnia
- Agitation
- Tremor
- Sweating
- Headache
- Dizziness
- Flushing
- Blurring of vision
- Nausea
- Dryness of the mouth
Serious adverse events
- Psychotic state
Drug interactions
- other anorectic agents
Key clinical trials
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Reinforcing Effects of Cocaine During Phendimetrazine Maintenance (PHASE1)
- Phendimetrazine and Cocaine (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENDIMETRAZINE TARTRATE CI brief — competitive landscape report
- PHENDIMETRAZINE TARTRATE updates RSS · CI watch RSS